SCHEMBL15375880

SCHEMBL15375880

CC(C)(C)OC(=O)N1CCC(Oc2ccc(C(=O)OCc3ccccc3)cc2)C1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.55
GPR119 Q8TDV5 4/20 0.52
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
FAAH O00519 1/20 0.47
EPHX2 P34913 1/20 0.47
YAP1 P46937 2/20 0.46
S1PR3 Q99500 1/20 0.46
LMNA P02545 1/20 0.46
CHEK2 O96017 1/20 0.45
STS P08842 1/20 0.45
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
BCHE P06276 1/20 0.45
PRMT5 O14744 1/20 0.45
CHRNB2 P17787 1/20 0.45
CHRNA5 P30532 1/20 0.45
CHRNA7 P36544 1/20 0.45
CHRNA4 P43681 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375881 1.00 USP30 (0.55) USP30GPR119JAK2JAK1FAAH
SCHEMBL15377844 1.00 USP30 (0.55) USP30GPR119JAK2JAK1FAAH
SCHEMBL21612907 0.92 USP30 (0.50) USP30GPR119JAK2JAK1FAAH
SCHEMBL23475143 0.89 USP30 (0.58) USP30GPR119JAK2JAK1YAP1
SCHEMBL6929071 0.88 USP30 (0.53) USP30GPR119JAK2JAK1YAP1
SCHEMBL21612929 0.87 SMN1; SMN2 (0.53) USP30GPR119FAAHEPHX2YAP1
SCHEMBL15531630 0.85 TDP1 (0.49) FAAHEPHX2LMNABCHECHRNB2
SCHEMBL21409063 0.84 USP30 (0.71) USP30GPR119JAK2JAK1KDM4E
SCHEMBL1769219 0.84 USP30 (0.71) USP30GPR119JAK2JAK1KDM4E
SCHEMBL5153452 0.84 USP30 (0.71) USP30GPR119JAK2JAK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170135994-A9 NAMPT INHIBITORS ABBVIE INC. (US) 2017-05-18 US disclosed
US-20160184282-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-30 US disclosed
US-20160184281-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-30 US disclosed
US-9193723-B2 NAMPT inhibitors ABBVIE INC. (US) 2015-11-24 US disclosed
US-9187472-B2 NAMPT inhibitors ABBVIE INC. (US) 2015-11-17 US disclosed
EP-2847192-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-03-18 EP disclosed
WO-2013170112-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO disclosed
US-20130303508-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 US disclosed
US-20130303511-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303508-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT USP30 4391/4885GPR119 662/4885JAK2 4255/4885
US-20160184282-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT USP30 4391/4885GPR119 662/4885JAK2 4255/4885
US-20130303511-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT USP30 4391/4885GPR119 662/4885JAK2 4255/4885
US-20160184281-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT USP30 4391/4885GPR119 662/4885JAK2 4255/4885
US-20170135994-A9 NAMPT INHIBITORS NAMPT, NNMT, NAPRT USP30 4391/4885GPR119 662/4885JAK2 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.